MedTrace Logo

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375

NCT04221360 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-01-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-375.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

CKD-375

Test drug, QD, PO

DRUG

D390

Reference drug, QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min Soo Park, M.D., Ph.D. · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-29
Primary Completion
2020-03-06
Completion
2020-06-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221360 on ClinicalTrials.gov